| Identification | Back Directory | [Name]
Sepranolone | [CAS]
1232861-58-3 | [Synonyms]
ONO-6950
Sepranolone
Gemilukast (ONO-6950)
SILHYVDKGHXGBL-UHFFFAOYSA-N
Gemilukast (Synonyms: ONO-6950)
1H-Indole-1,3-dibutanoic acid, 4-fluoro-7-[2-[4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl]ethynyl]-2-methyl- | [Molecular Formula]
C36H37F2NO5 | [MDL Number]
MFCD28963982 | [MOL File]
1232861-58-3.mol | [Molecular Weight]
601.68 |
| Chemical Properties | Back Directory | [Boiling point ]
806.6±65.0 °C(Predicted) | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (415.50 mM) | [form ]
Solid | [pka]
4.72±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively. Gemilukast is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
Gemilukast at 0.03 to 10 mg/kg, p.o. dose-dependently attenuates LTC4-induced bronchoconstriction with almost complete inhibition at 3 mg/kg. The inhibitory effect of Gemilukast on LTC4-induced bronchoconstriction is significantly stronger than that of montelukast at the dose of 1 mg/kg or more. Gemilukast (0.03 to 1 mg/kg, p.o.) dose-dependently attenuates LTD4-induced airway vascular hyperpermeability with complete inhibition at 0.3 mg/kg. Gemilukast at 0.1 to 3 mg/kg, p.o. dose-dependently inhibits OVA-induced bronchoconstriction. The inhibitory effect of Gemilukast at 3 mg/kg is significantly greater than that of montelukast alone and comparable to that of combination therapy with montelukast and BayCysLT2RA[2]. | [IC 50]
CysLT1: 1.7 nM (IC50); CysLT2: 25 nM (IC50) | [References]
[1] Itadani S, et al. Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem. 2015 Aug 13;58(15):6093-113. DOI:10.1021/acs.jmedchem.5b00741
[2] Yonetomi Y, et al. Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma. Eur J Pharmacol. 2015 Oct 15;765:242-8. DOI:10.1016/j.ejphar.2015.08.041 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|